Chronic leukaemias in the community

Eric Wenlong Li, David Yeung, Stephen Fuller

Research output: Contribution to journalArticlepeer-review


Patients with chronic myeloid leukaemia and chronic lymphocytic leukaemia are now predominantly managed in an outpatient setting, with infrequent need for hospital-based therapNew targeted oral treatments have transformed survival outcomes. An increasing number of patients now have a life expectancy approaching that of the general population. Suboptimal drug adherence is common and a key reason for therapy failure and poor clinical outcomes. The pharmacokinetics of new oral targeted drugs are significantly impacted by drug–drug interactions and an altered gastric pH. Long-term use of some of the new oral drugs is associated with complications, including cardiovascular events and infections, which can be fatal if not recognised.

Original languageEnglish
Pages (from-to)126-130
Number of pages5
JournalAustralian Prescriber
Issue number4
Publication statusPublished or Issued - Aug 2020


  • Chronic lymphocytic leukaemia
  • Chronic myeloid leukaemia
  • Drug interactions
  • Patient adherence
  • Targeted therapy
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this